Literature DB >> 35023971

Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.

JunJie Yu1, WeiPu Mao1, Si Sun1, Qiang Hu1, Can Wang1, ZhiPeng Xu1, RuiJi Liu1, SaiSai Chen1, Bin Xu2,3, Ming Chen2,4.   

Abstract

PURPOSE: The study aimed to identify an autophagy-related molecular subtype and characterize a novel defined autophagy-immune related genes score (AI-score) signature and prognosis model in bladder cancer (BLCA) patients using public databases.
METHODS: The transcriptome cohorts downloaded from TCGA and GEO database were carried out with genomic analysis and unsupervised methods to obtain autophagy-related molecular subtypes. The single-sample gene-set enrichment analysis (ssGSEA) was utilized to perform immune subtype clustering. We defined a novel autophagy subtype and evaluated the role in TME cell infiltration. Then, the principal-component analysis (PCA) was applied to construct an AI-score signature. Subsequently, two immunotherapeutic cohorts were used to evaluate the predictive value in immunotherapeutic benefits and immune response. Finally, univariate, Lasso and multivariate Cox regression algorithm were used to construct and evaluate an autophagy-immune-related genes prognosis model. Also, qRT-PCR and IHC was applied to validate the expression of the 6 genes in the model.
RESULTS: Three distinct autophagy clusters and immune-related clusters were identified, and a novel autophagy-related molecular subtypes were defined. Furthermore, the roles in TME cell infiltration and clinical traits for the autophagy subtypes were characterized. Meanwhile, we constructed an AI-score signature and demonstrated it could predict genetic mutation, clinicopathological traits, prognosis, and TME stromal activity. We found that it could accurately predict the clinicopathological characteristics and immune response of individual BLCA patients and provide guidance for selecting immunotherapy. Ultimately, we constructed and verified an autophagy-immune-related prognostic model of BLCA patients and established a prognostic nomogram with a good prediction accuracy.
CONCLUSION: We constructed AI-score signatures and prognosis risk model to characterize their role in clinical features and TME immune cell infiltration. It revealed that the AI-score signature and prognosis model could be a valid predictive tool, which could accurately predict the prognosis of BLCA patients and contribute to choosing effective personalized immunotherapy strategies.
© 2022 Yu et al.

Entities:  

Keywords:  Gene Expression Omnibus; The Cancer Genome Atlas; bladder cancer; immunotherapy; mutation burden; tumor microenvironment

Year:  2022        PMID: 35023971      PMCID: PMC8743383          DOI: 10.2147/CMAR.S346240

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  50 in total

Review 1.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 2.  Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.

Authors:  Jakub Dobruch; Siamak Daneshmand; Margit Fisch; Yair Lotan; Aidan P Noon; Matthew J Resnick; Shahrokh F Shariat; Alexandre R Zlotta; Stephen A Boorjian
Journal:  Eur Urol       Date:  2015-09-04       Impact factor: 20.096

3.  Identification of autophagy-related genes signature predicts chemotherapeutic and immunotherapeutic efficiency in bladder cancer (BLCA).

Authors:  Rui Cao; Bo Ma; Gang Wang; Yaoyi Xiong; Ye Tian; Lushun Yuan
Journal:  J Cell Mol Med       Date:  2021-05-07       Impact factor: 5.310

4.  Autophagy enhances mesenchymal stem cell-mediated CD4+ T cell migration and differentiation through CXCL8 and TGF-β1.

Authors:  Shuizhong Cen; Peng Wang; Zhongyu Xie; Rui Yang; Jinteng Li; Zhenhua Liu; Shan Wang; Xiaohua Wu; Wenjie Liu; Ming Li; Su'an Tang; Huiyong Shen; Yanfeng Wu
Journal:  Stem Cell Res Ther       Date:  2019-08-23       Impact factor: 6.832

5.  m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer.

Authors:  Bo Zhang; Qiong Wu; Ben Li; Defeng Wang; Lei Wang; You Lang Zhou
Journal:  Mol Cancer       Date:  2020-03-12       Impact factor: 27.401

6.  Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance.

Authors:  Quan Zhou; Zewei Wang; Han Zeng; Hongyu Zhang; Zhaopei Liu; Qiuren Huang; Jiajun Wang; Yuan Chang; Qi Bai; Li Liu; Yu Zhu; Le Xu; Bo Dai; Jianming Guo; Yu Xia; Yiwei Wang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2020-04-03       Impact factor: 8.110

7.  NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR.

Authors:  Ruihui Xie; Xu Chen; Liang Cheng; Ming Huang; Qianghua Zhou; Jingtong Zhang; Yuelong Chen; Shengmeng Peng; Ziyue Chen; Wen Dong; Jian Huang; Tianxin Lin
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

8.  GSVA: gene set variation analysis for microarray and RNA-seq data.

Authors:  Sonja Hänzelmann; Robert Castelo; Justin Guinney
Journal:  BMC Bioinformatics       Date:  2013-01-16       Impact factor: 3.169

9.  An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).

Authors:  Wen Jiang; Dandan Zhu; Chenghe Wang; Yu Zhu
Journal:  Cancer Med       Date:  2020-02-25       Impact factor: 4.452

10.  A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Authors:  Aurélie Kamoun; Aurélien de Reyniès; Yves Allory; Gottfrid Sjödahl; A Gordon Robertson; Roland Seiler; Katherine A Hoadley; Clarice S Groeneveld; Hikmat Al-Ahmadie; Woonyoung Choi; Mauro A A Castro; Jacqueline Fontugne; Pontus Eriksson; Qianxing Mo; Jordan Kardos; Alexandre Zlotta; Arndt Hartmann; Colin P Dinney; Joaquim Bellmunt; Thomas Powles; Núria Malats; Keith S Chan; William Y Kim; David J McConkey; Peter C Black; Lars Dyrskjøt; Mattias Höglund; Seth P Lerner; Francisco X Real; François Radvanyi
Journal:  Eur Urol       Date:  2019-09-26       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.